Article
Effects of genetic variants on platelet reactivity and one-year clinical outcomes after percutaneous coronary intervention: A prospective multicentre registry study.
Scientific reports - 19 Jan 2018
Joo Hyung Joon, Ahn Sung Gyun, Park Jae Hyoung, Park Ji Young, Hong Soon Jun, Kim Seok-Yeon, Choi WoongGil, Gwon HyeonCheol, Lim Young-Hyo, Kim Weon, Kang Woong Chol, Cho Yun-Hyeong, Kim Yong Hoon, Yoon JungHan, Shin WonYong, Hong Myeong-Ki, Garg Scot, Jang Yangsoo, Lim Do-Sun
Abstract excerpt
Clopidogrel is the mainstay for antiplatelet treatment after percutaneous coronary intervention (PCI). The relationship of platelet reactivity and genetic polymorphism with clinical outcomes with newer-generation drug-eluting stents is unclear. We analysed 4,587 patients for the most powerful single-nucleotide polymorphisms (CYP2C19, CYP2C9, ABCB1, PON1, and P2Y12) related to on-treatment platelet reactivity...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.
